



UNIVERSITÀ
degli STUDI
di CATANIA

Multivessel PCI in AMI and Cardiogenic Shock: SHOCK Trial Series Review and Real-World Application

Davide Capodanno, MD, PhD

Division of Cardiology, C.A.S.T.
University Hospital of Catania, Italy

Disclosure Statement of Financial Interest

Within the past 12 months, I, **Davide Capodanno**, have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial relationship

Company

Speakers' honoraria

AstraZeneca, Abbott Vascular, Bayer, Sanofi
Aventis

Consulting

Abbott Vascular, Bayer

Advisory Board

Abbott Vascular, AstraZeneca, Bayer

Key Lessons in AMI with Cardiogenic Shock

1. Early Revascularization Reduces Mortality

SHOCK trial: 302 patients with STEMI and cardiogenic shock randomized to either revascularization (accomplished by CABG or angioplasty) or medical therapy

Outcome and subgroup	Revascularization	Medical therapy	Relative risk (95% CI)	P Value
30-day death	46.7%	56.0%	0.83 (0.67-1.04)	0.11
6-month death	50.3%	63.1%	0.80 (0.65-0.98)	0.027

Key Lessons in AMI with Cardiogenic Shock


2. IABP Does Not Reduce Mortality

IABP-SHOCK II: 600 patients with AMI and cardiogenic shock undergoing early revascularization randomized to either IABP or not IABP


Outcome and subgroup	IABP	No IABP	Relative risk (95% CI)	P Value
30-day death	39.7%	41.3%	0.96 (0.79-1.17)	0.69

Multivessel Disease in Acute Myocardial Infarction

STEMI without cardiogenic shock



STEMI with cardiogenic shock



Recommendations for Multivessel PCI With Acute Myocardial Infarction With Cardiogenic Shock

2017 ESC Guidelines for ST-segment Elevation Myocardial Infarction

Recommendation	Class	LOE
Non-IRA PCI during the index procedure should be considered in patients with cardiogenic shock.	Ia	C



Recommendations for Multivessel PCI With Acute Myocardial Infarction WITHOUT Cardiogenic Shock

2017 ESC Guidelines for ST-segment Elevation Myocardial Infarction

Recommendation	Class	LOE
Routine revascularization of non-IRA lesions should be considered in STEMI patients with multivessel disease before hospital discharge.	Ia	A

- ▶ Politi et al. Heart 2010
- ▶ PRAMI NEJM 2013
- ▶ CvLPRIT JACC 2015
- ▶ DANAMI 3 Lancet 2015
- ▶ COMPARE-ACUTE NEJM 2017




CULPRIT-SHOCK: Patients Disposition

1075 patients with acute myocardial infarction (STEMI and NSTEMI) and cardiogenic shock screened

369 excluded

706 randomized



CULPRIT-SHOCK: Baseline Characteristics

Characteristic	Culprit only PCI (n=344)	Multivessel PCI (n=342)
Age (years); median (IQR)	70 (60-78)	70 (60-77)
Male sex; n/total (%)	257/343 (74.9)	267/342 (78.1)
Prior myocardial infarction; n/total (%)	60/339 (17.7)	53/335 (15.8)
Prior PCI; n/total (%)	64/339 (18.9)	63/335 (18.8)
Prior coronary arterial bypass surgery; n/total (%)	20/341 (5.9)	13/337 (3.9)
Signs of impaired organ perfusion; n/total (%)		
Altered mental status	237/341 (69.5)	224/341 (65.7)
Cold, clammy skin and extremities	233/338 (68.9)	236/335 (70.4)
Oliguria	80/334 (24.0)	93/326 (28.5)
Arterial lactate >2.0 mmol/l	216/334 (64.7)	224/330 (67.9)
Fibrinolysis <24 h before randomization; n/total (%)	19/341 (5.6)	15/341 (4.4)
Resuscitation before randomization; n/total (%)	177/341 (51.9)	189/342 (55.3)
ST-elevation myocardial infarction; n/total (%)	206/335 (61.5)	209/330 (63.3)
No. of diseased vessels; n/total (%)		
1	3/343 (0.9)	2/342 (0.6)
2	122/343 (35.6)	124/342 (36.3)
3	218/343 (63.6)	216/342 (63.2)
Patients with at least one CTO; n/total (%)	77/344 (22.4)	82/342 (24.0)
Left ventricular ejection fraction (%); median (IQR)	33 (25-40)	30 (21-40)

CULPRIT-SHOCK: Baseline Characteristics

Characteristic	Culprit only PCI (n=344)	Multivessel PCI (n=342)
Age (years); median (IQR)	70 (60-78)	70 (60-77)
Male sex; n/total (%)	257/343 (74.9)	267/342 (78.1)
Prior myocardial infarction; n/total (%)	60/339 (17.7)	53/335 (15.8)
Prior PCI; n/total (%)	64/339 (18.9)	63/335 (18.8)
Prior coronary arterial bypass surgery; n/total (%)	20/341 (5.9)	13/337 (3.9)
Signs of impaired organ perfusion; n/total (%)		
Altered mental status	237/341 (69.5)	224/341 (65.7)
Cold, clammy skin and extremities	233/338 (68.9)	236/335 (70.4)
Oliguria	80/334 (24.0)	93/326 (28.5)
Arterial lactate >2.0 mmol/l	216/334 (64.7)	224/330 (67.9)
Fibrinolysis <24 h before randomization; n/total (%)	19/341 (5.6)	15/341 (4.4)
Resuscitation before randomization; n/total (%)	177/341 (51.9)	189/342 (55.3)
ST-elevation myocardial infarction; n/total (%)	206/335 (61.5)	209/330 (63.3)
No. of diseased vessels; n/total (%)		
1	3/343 (0.9)	2/342 (0.6)
2	122/343 (35.6)	124/342 (36.3)
3	218/343 (63.6)	216/342 (63.2)
Patients with at least one CTO; n/total (%)	77/344 (22.4)	82/342 (24.0)
Left ventricular ejection fraction (%); median (IQR)	33 (25-40)	30 (21-40)

CULPRIT-SHOCK: Treatment

Characteristic	Culprit only PCI (n=344)	Multivessel PCI (n=342)	P value
Femoral access; n/total (%)	287/343 (83.7)	277/342 (81.0)	0.36
Radial access; n/total (%)	61/343 (17.8)	66/342 (19.3)	0.61
Stent implanted in culprit lesion; n/total (%)	326/343 (95.0)	324/342 (94.7)	0.86
Drug-eluting stent in culprit lesion; n/total (%)	305/326 (93.6)	308/324 (95.1)	0.41
TIMI-flow III post PCI of culprit lesion; n/total (%)	289/342 (84.5)	293/338 (86.7)	0.46
Immediate PCI of non-culprit lesions; n/total (%)	43/344 (12.5)	310/342 (90.6)	<0.001
Immediate complete revascularization; n/total (%)	26/344 (7.6)	277/342 (81.2)	<0.001
Total amount of contrast agent (ml); median (IQR)	190 (140-250)	250 (200-350)	<0.001
Staged PCI of non-culprit lesions; n/total (%)	60/344 (17.4)	8/341 (2.3)	<0.001
Staged coronary artery bypass surgery; n/total (%)	1/344 (0.3)	0/341	>0.99
Mechanical circulatory support; n/total (%)	99/344 (28.8)	95/342 (27.8)	0.77
Intraaortic balloon pump; n/total (%)	25/99 (25.3)	26/95 (27.4)	0.74
Impella 2.5; n/total (%)	16/99 (16.2)	18/95 (18.9)	0.61
Impella CP; n/total (%)	30/99 (30.3)	18/95 (18.9)	0.07
TandemHeart; n/total (%)	2/99 (2.0)	0/95	0.50
ECMO; n/total (%)	18/99 (18.2)	27/95 (28.4)	0.09
Mild hypothermia; n/total (%)	111/344 (32.3)	118/340 (34.7)	0.50
Mechanical ventilation; n/total (%)	273/344 (79.4)	282/339 (83.2)	0.20
Duration of mechanical ventilation (days); median (IQR)	3 (1-7)	3 (1-7)	0.97
Duration of intensive care treatment (days); median (IQR)	5 (2-12)	5 (2-11)	0.61

Thiele H, et al. N Engl J Med. 2017;377:2419-2432

CULPRIT-SHOCK: Treatment


Characteristic	Culprit only PCI (n=344)	Multivessel PCI (n=342)	P value
Femoral access; n/total (%)	287/343 (83.7)	277/342 (81.0)	0.36
Radial access; n/total (%)	61/343 (17.8)	66/342 (19.3)	0.61
Stent implanted in culprit lesion; n/total (%)	326/343 (95.0)	324/342 (94.7)	0.86
Drug-eluting stent in culprit lesion; n/total (%)	305/326 (93.6)	308/324 (95.1)	0.41
TIMI-flow III post PCI of culprit lesion; n/total (%)	289/342 (84.5)	293/338 (86.7)	0.46
Immediate PCI of non-culprit lesions; n/total (%)	43/344 (12.5)	310/342 (90.6)	<0.001
Immediate complete revascularization; n/total (%)	26/344 (7.6)	277/342 (81.2)	<0.001
Total amount of contrast agent (ml); median (IQR)	190 (140-250)	250 (200-350)	<0.001
Staged PCI of non-culprit lesions; n/total (%)	60/344 (17.4)	8/341 (2.3)	<0.001
Staged coronary artery bypass surgery; n/total (%)	1/344 (0.3)	0/341	>0.99
Mechanical circulatory support; n/total (%)	99/344 (28.8)	95/342 (27.8)	0.77
Intraaortic balloon pump; n/total (%)	25/99 (25.3)	26/95 (27.4)	0.74
Impella 2.5; n/total (%)	16/99 (16.2)	18/95 (18.9)	0.61
Impella CP; n/total (%)	30/99 (30.3)	18/95 (18.9)	0.07
TandemHeart; n/total (%)	2/99 (2.0)	0/95	0.50
ECMO; n/total (%)	18/99 (18.2)	27/95 (28.4)	0.09
Mild hypothermia; n/total (%)	111/344 (32.3)	118/340 (34.7)	0.50
Mechanical ventilation; n/total (%)	273/344 (79.4)	282/339 (83.2)	0.20
Duration of mechanical ventilation (days); median (IQR)	3 (1-7)	3 (1-7)	0.97
Duration of intensive care treatment (days); median (IQR)	5 (2-12)	5 (2-11)	0.61

Thiele H, et al. *N Engl J Med.* 2017;377:2419-2432

CULPRIT-SHOCK: Primary Endpoint

706 patients with MVD, AMI, and cardiogenic shock randomized to either PCI of the culprit lesion only or immediate multivessel PCI


All-cause mortality or renal replacement therapy at 30 days




CULPRIT-SHOCK: Secondary Outcomes

706 patients with MVD, AMI, and cardiogenic shock randomized to either PCI of the culprit lesion only or immediate multivessel PCI

All-cause mortality



Renal replacement therapy




CULPRIT-SHOCK: Other Secondary Outcomes

706 patients with MVD, AMI, and cardiogenic shock randomized to either PCI of the culprit lesion only or immediate multivessel PCI

Outcome	Culprit-Lesion-Only PCI Group (N = 344)	Multivessel PCI Group (N = 341)	P Value
Recurrent myocardial infarction	1.2%	0.9%	1.00
Rehospitalization for congestive heart failure	0.3%	0.3%	0.99
Death, recurrent myocardial infarction, or rehospitalization for congestive heart failure	43.9%	52.3%	0.03
Staged or urgent repeat revascularization	21.5%	3.8%	<0.001
Stroke	3.5%	2.9%	0.68
BARC type 2, 3, or 5 bleeding	16.6%	22.0%	0.07


CULPRIT-SHOCK: Causes of Death

706 patients with MVD, AMI, and cardiogenic shock randomized to either PCI of the culprit lesion only or immediate multivessel PCI



CULPRIT-SHOCK: Glomerular Filtration Rate


706 patients with MVD, AMI, and cardiogenic shock randomized to either PCI of the culprit lesion only or immediate multivessel PCI



Was There an Influence of CTOs on Outcomes?

- ▶ CTO presence was not defined as an exclusion criterion in CULPRIT-SHOCK, because exclusion of CTO would have led to a major selection bias and a lower-risk cohort.
 - It was recommended to intervene on the CTO as easily as possible, with a limit of contrast agent of 300 cm³ for the overall immediate multivessel PCI procedure and no retrograde or other complex interventional approaches were recommended.
 - At least 1 CTO was present in 22.4% in the culprit-lesion-only arm and in 24.0% in the immediate multivessel PCI arm. Immediate CTO recanalization was attempted in roughly 50% of patients in the immediate multivessel PCI group and was successful in approximately one third of attempts.

CULPRIT-SHOCK: Subgroups Analysis



A “Real World” Series of Cardiogenic Shock

KAMIR-NIH registry: 659 pts who underwent multivessel PCI (39.5%) or infarct-related artery (IRA)-only PCI (60.5%) between Nov 2011 and Dec 2015

Outcome	Multivessel PCI (N = 260)	IRA-only PCI (N = 399)	Adjusted HR (95% CI)	P value
All-cause death	21.3%	31.7%	0.52 (0.38–0.73)	<0.001
Cardiac death	17.4%	27.5%	0.53 (0.37–0.77)	0.001
Recurrent MI	2.2%	3.3%	0.65 (0.20–2.09)	0.47
Any revascularization	11.6%	16.5%	0.50 (0.27–0.93)	0.027
Non-IRA revascularization	6.7%	8.2%	0.33 (0.14–0.78)	0.011
Definite or probable ST	1.4%	1.4%	0.53 (0.04–7.89)	0.65
Death or MI	22.4%	33.9%	0.57 (0.42–0.79)	0.001
Death or new RRT	21.3%	32.6%	0.52 (0.37–0.72)	<0.001
POCE	28.4%	42.6%	0.58 (0.40–0.83)	0.003

How Can We Solve this Discrepancy?

	CULPRIT-SHOCK	KAMIR-NIH
Type	RCT	Registry
Patients	706	659
30-day mortality	47.4%	21.9%
Mechanical circulatory support	28%	27%
IRA-only PCI	50%	60.6%
Multivessel PCI	50%	39.4%
Immediate multivessel PCI	90.6%	60.4%
Staged non-IRA PCI	2.3%	39.6%
Complete revascularization	81% (immediate)	65.8%
CTO	24%	NR
CTO-PCI	~12%	NR
CTO-PCI success	~4%	NR

Recommendations for Multivessel PCI With Acute Myocardial Infarction and Cardiogenic Shock

Current Recommendation (2017)	Class	LOE
Non-IRA PCI during the index procedure should be considered in patients with cardiogenic shock.	IIa	C



Potential Update (?)	Class	LOE
PCI limited to the culprit lesion is recommended on a routine basis with an option for staged revascularization.	I	A or B
Routine immediate multivessel PCI is not recommended in patients with cardiogenic shock.	III	B

► CULPRIT-SHOCK

Closing Remarks

- ▶ Based on CULPRIT-SHOCK, culprit-lesion-only PCI with possible staged revascularization should be the preferred revascularization strategy, which can also be translated as “keep the revascularization strategy simple.”
- ▶ However, areas of uncertainty remain:
 1. What are the underlying mechanisms for the observed difference in mortality?
 2. Would complete revascularization by CABG make a difference?
 3. What is the optimal timing for staged revascularization in cardiogenic shock patients?
 4. Any difference in outcomes with timely initiation of powerful mechanical circulatory support?